Cytosorbents Corp
NASDAQ:CTSO
Earnings Announcements
CytoSorbents Reports Preliminary Fourth Quarter And Full Year 2022 Revenue
Published: 01/31/2023 14:26 GMT
Cytosorbents Corp (CTSO) - Cytosorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue.
Cytosorbents Corp - Q4 2022 Product Sales Rebounded From Q3 2022 Low.
Cytosorbents Corp - Adjusted for Constant Currency, Core Non-covid 2022 Product Sales Were Within 5% of That Achieved in 2021.
Cytosorbents Corp - Q4 2022 Total Revenue Was Approximately $9.4 Million Versus $10.8 Million in Q4 2021.
Cytosorbents Corp - Q4 2022 Product Sales Rebounded From Q3 2022 Low.
Cytosorbents Corp - Adjusted for Constant Currency, Core Non-covid 2022 Product Sales Were Within 5% of That Achieved in 2021.
Cytosorbents Corp - Q4 2022 Total Revenue Was Approximately $9.4 Million Versus $10.8 Million in Q4 2021.
Revenue is expected to be $8.74 Million
Adjusted EPS is expected to be -$0.13
Next Quarter Revenue Guidance is expected to be $9.36 Million
Next Quarter EPS Guidance is expected to be -$0.12
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.13
Next Quarter Revenue Guidance is expected to be $9.36 Million
Next Quarter EPS Guidance is expected to be -$0.12
More details on our Analysts Page.